Chimeric Monkeys Born in Stem Cell Study
By Dan Vergano,
USA Today
| 01. 05. 2012
Biologists report the
first monkey "chimeras", born with a mix of genes in their cells.
The monkeys were born from mixtures of very-early stage embryonic cells. That suggests that primate (including human) embryonic stem cells may have developmental differences not present in mouse stem cells, ones seen as their equivalents in research until now. Also, the research points to a new strategy for cloning primates using embryonic cells, say the study authors, an achievement that has eluded researchers for more than a decade.
Reported by the journal Cell, the study team led by stem cell developmental biologist Masahito Tachibana of the Oregon National Primate Research Center, reports three healthy male monkeys were born from their efforts. Rather than using embryonic stem cells cultured from lines of cells grown in petri dishes, the researchers used early-stage stem cells taken directly from monkey four-cell embryos to create 10 chimeric, or genetically mixed, embryos. The teams combined cells taken from different early-stage embryos to make new chimeric ones, and then implanted them into female monkeys.
Three of the embryos were carried...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...